Expression and purification of recombinant Kaposi's sarcoma-associated herpesvirus DNA polymerase using a Baculovirus vector system

被引:4
作者
Dorjsuren, D
Badralmaa, Y
Mikovits, J
Li, AQ
Fisher, R
Ricciardi, R
Shoemaker, R
Sei, S
机构
[1] SAIC Frederick, Lab Antiviral Drug Mech, Ft Detrick, MD 21702 USA
[2] SAIC Frederick, Clin Serv Program, Lab Mol Cell Biol, Ft Detrick, MD 21702 USA
[3] SAIC Frederick, Prot Chem Lab, Ft Detrick, MD 21702 USA
[4] Univ Penn, Dept Microbiol, Philadelphia, PA USA
[5] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA USA
[6] NCI Frederick, Screening Technol Branch, Dev Therapeut Program, Ft Detrick, MD 21702 USA
关键词
D O I
10.1016/S1046-5928(03)00017-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The DNA polymerase (POL) of Kaposi's sarcoma-associated herpesvirus (KSHV) is essential for viral DNA replication and, thus, may be considered as a viable target for anti-KSHV therapeutics. To produce large quantities of homogeneous and pure POL required for high-throughput screening (HTS) for inhibitors, we generated a recombinant baculovirus vector encoding a hexahistidine (His6)-tagged POL and infected Spodoptera frugiperda Sf-9 insect cells. High expression of recombinant POL (rPOL) was achieved for up to 72h post-infection. The rPOL was solubilized in lysis buffer containing 0.3% Cymal-5 detergent, purified by metal-chelating and dsDNA-cellulose affinity chromatography, and analyzed by anti-His antibody Western blot and mass spectrometry. The functionality of rPOL was confirmed by its DNA synthesis activity in vitro, which was effectively blocked by the antiherpetic DNA polymerase inhibitors, foscarnet and cidofovir diphosphate, in a dose-dependent manner. The POL expressed and purified from the recombinant baculovirus-infected insect cells may be useful toward the development of FITS of large chemical libraries to identify novel KSHV DNA polymerase inhibitors. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:42 / 50
页数:9
相关论文
共 35 条
[1]  
Anderson D., 1995, Focus Madison, V17, P53
[2]  
Cesarman E, 1996, AM J PATHOL, V149, P53
[3]   KAPOSIS SARCOMA-ASSOCIATED HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-RELATED BODY-CAVITY-BASED LYMPHOMAS [J].
CESARMAN, E ;
CHANG, Y ;
MOORE, PS ;
SAID, JW ;
KNOWLES, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (18) :1186-1191
[4]   IDENTIFICATION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-ASSOCIATED KAPOSIS-SARCOMA [J].
CHANG, Y ;
CESARMAN, E ;
PESSIN, MS ;
LEE, F ;
CULPEPPER, J ;
KNOWLES, DM ;
MOORE, PS .
SCIENCE, 1994, 266 (5192) :1865-1869
[5]   New anti-HSV therapeutics target the helicase primase complex [J].
Crumpacker, CS ;
Schaffer, PA .
NATURE MEDICINE, 2002, 8 (04) :327-328
[6]   Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease [J].
Crute, JJ ;
Grygon, CA ;
Hargrave, KD ;
Simoneau, B ;
Faucher, AM ;
Bolger, G ;
Kibler, P ;
Liuzzi, M ;
Cordingley, MG .
NATURE MEDICINE, 2002, 8 (04) :386-391
[7]   Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8 [J].
De Clercq, E ;
Naesens, L ;
De Bolle, L ;
Schols, D ;
Zhang, Y ;
Neyts, J .
REVIEWS IN MEDICAL VIROLOGY, 2001, 11 (06) :381-395
[8]   THE EXTREME-C TERMINUS OF HERPES-SIMPLEX VIRUS-DNA POLYMERASE IS CRUCIAL FOR FUNCTIONAL INTERACTION WITH PROCESSIVITY FACTOR-UL42 AND FOR VIRAL REPLICATION [J].
DIGARD, P ;
BEBRIN, WR ;
WEISSHART, K ;
COEN, DM .
JOURNAL OF VIROLOGY, 1993, 67 (01) :398-406
[9]   Biology of Kaposi's sarcoma [J].
Ensoli, B ;
Sgadari, C ;
Barillari, G ;
Sirianni, MC ;
Stürzl, M ;
Monini, P .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (10) :1251-1269
[10]   IDENTIFICATION AND CHARACTERIZATION OF ORILYT, A LYTIC ORIGIN OF DNA-REPLICATION OF EPSTEIN-BARR VIRUS [J].
HAMMERSCHMIDT, W ;
SUGDEN, B .
CELL, 1988, 55 (03) :427-433